|
|
|
|
| LEADER |
06133nam a2200721 4500 |
| 001 |
ocn889271702 |
| 003 |
OCoLC |
| 005 |
20180501122021.0 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
140805t20142014cauaf ob 001 0 eng d |
| 040 |
|
|
|a E7B
|b eng
|e rda
|e pn
|c E7B
|d OCLCO
|d UIU
|d N$T
|d YDXCP
|d OCLCF
|d OCLCQ
|d EBLCP
|d OHS
|d DEBSZ
|d CASUM
|d OCLCQ
|d OCLCO
|d OCLCA
|d FEM
|d OCLCQ
|d OCLCO
|d OCLCA
|d MERUC
|d OCLCO
|d MEU
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 885123479
|a 960214102
|a 968117026
|a 968993773
|a 1027704072
|
| 020 |
|
|
|a 9780128003930
|q (electronic bk.)
|
| 020 |
|
|
|a 0128003936
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128000922
|
| 020 |
|
|
|a 0128000929
|
| 035 |
|
|
|a (OCoLC)889271702
|z (OCoLC)885123479
|z (OCoLC)960214102
|z (OCoLC)968117026
|z (OCoLC)968993773
|z (OCoLC)1027704072
|
| 050 |
|
4 |
|a RC270.8
|b .H935 eb
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99406
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Hyaluronan signaling and turnover /
|c edited by Melanie A. Simpson, Paraskevi Heldin.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a San Diego, California :
|b Elsevier,
|c 2014.
|
| 264 |
|
4 |
|c ©2014
|
| 300 |
|
|
|a 1 online resource (418 pages, 26 unnumbered pages of plates) :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|2 rda
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ebrary, viewed August 5, 2014).
|
| 505 |
0 |
|
|a Front Cover; Hyaluronan Signaling and Turnover; Copyright; Contents; Contributors; Preface; Chapter One: Emerging Roles for Hyaluronidase in Cancer Metastasis and Therapy; 1. Introduction; 2. Of Mole Rats and Men: Insights About HA and Cancer; 2.1. HA and hyaluronidase accelerate human cancers; 2.2. Naked mole rats resist cancer; 3. Hyaluronidase Expression in Cancer; 3.1. Hyal1; 3.2. Hyal2; 3.3. Hyal3, Hyal4, and PH-20; 4. Hyaluronidase Function and the Metastatic Process; 4.1. Vesicle trafficking and cell motility; 4.2. Vesicle shedding.
|
| 505 |
8 |
|
|a 4.3. Products of hyaluronidase: Fragments versus oligos4.4. Products of hyaluronidase: Beyond HA; 5. Hyaluronidase Targeting in Cancer Therapy and Imaging; 5.1. Structural and functional features of human Hyals; 5.2. Targeting of hyaluronidase for cancer therapy; 5.3. Hyaluronidase-targeting agents for tumor imaging; 6. Conclusions and Future Perspective; Acknowledgments; References; Chapter Two: Targeting Hyaluronic Acid Family for Cancer Chemoprevention and Therapy; 1. Introduction; 2. Targeting HA Production; 2.1. Targeting HA synthases; 2.2. Chemical inhibitors of HA synthesis.
|
| 505 |
8 |
|
|a 2.2.1. 4-Methylumbelliferone2.2.2. Other HA synthesis inhibitors; 3. Targeting HA Signaling; 3.1. HA oligosaccharides; 4. HA as a Carrier for Drug Delivery; 5. Targeting HA Receptors; 5.1. CD44; 5.1.1. CD44 vaccines; 5.1.2. CD44 siRNA delivery; 5.1.3. Targeting CD44 for delivering antitumor therapies; 5.1.4. Targeting of CD44 protein; 5.2. RHAMM; 6. Targeting HAase; 7. Conclusion; Acknowledgments; References; Chapter Three: Aberrant Posttranscriptional Processing of Hyaluronan Synthase 1 in Malignant Transformation and Tumor Prog ... ; 1. Splicing and Cancer; 1.1. Splicing in the human genome.
|
| 505 |
8 |
|
|a 2. Control of Pre-mRNA Splicing2.1. Splicing mutations; 3. Impact on Cancer of Alterations in Splicing Machinery; 4. Aberrant Splicing of Hyaluronan Synthase 1; 4.1. B lineage malignancies; 4.1.1. Multiple myeloma; 4.1.2. Waldenstrom macroglobulinemia; 4.2. Aberrant splice variants in hyaluronan synthase 1; 5. Clinical Impact of Aberrant HAS1 Splicing; 6. Genetic Variations in HAS1; 7. Functional Impact of HAS1Vs; 7.1. Synthesis of HA; 7.2. Functional outcomes of HA synthesis in patients; 7.2.1. Motility and malignant spread; 7.2.2. HAS1Vs and oncogenic events.
|
| 505 |
8 |
|
|a 7.2.3. Intermolecular interactions of HAS1Vs7.2.4. HAS1Vs and genetic instability; 8. Functional Outcomes of HAS1Vs in Transfectants; 8.1. HAS1Vs synthesize intracellular HA; 8.2. HAS1FL and HAS1Vs form heteromultimers with HAS1Vs as the dominant partners; 8.3. Multimers with HAS1Vs stabilize HAS1FL and maintain intracellular HA; 9. HAS1Vs and Mitotic Catastrophe; 9.1. A potential mechanism underlying the oncogenic properties of aberrant HAS1 splice variants: HAS1V-mediated rescue fro ... ; 9.1.1. Receptor for hyaluronan-mediated motility (RHAMM).
|
| 520 |
|
|
|a Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers hyaluronan signaling and turnover. Provides information on cancer research Outstanding and original reviews Suitable for researchers and students.
|
| 546 |
|
|
|a Text in English.
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|
| 650 |
|
0 |
|a Cancer.
|
| 650 |
1 |
2 |
|a Hyaluronic Acid
|x physiology.
|0 (DNLM)D006820Q000502
|
| 650 |
1 |
2 |
|a Neoplasms.
|0 (DNLM)D009369
|
| 650 |
2 |
2 |
|a Medical Oncology.
|0 (DNLM)D008495
|
| 650 |
2 |
2 |
|a Signal Transduction.
|0 (DNLM)D015398
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer.
|2 fast
|0 (OCoLC)fst00845317
|
| 650 |
|
7 |
|a Cancer
|x Treatment.
|2 fast
|0 (OCoLC)fst00845538
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Simpson, Melanie A.,
|e editor.
|
| 700 |
1 |
|
|a Heldin, Paraskevi,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Hyaluronan signaling and turnover.
|b First edition.
|d San Diego, California : Elsevier, ©2014
|h xvi, 385 pages
|k Advances In Cancer Research ; Volume 123
|x 0065-230X
|z 9780128000922
|
| 830 |
|
0 |
|a Advances in cancer research ;
|v v. 123.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/0065230X/123
|z Full Text via HEAL-Link
|
